This page shows the publications co-authored by Gordon Harris and Miriam Bredella.
Management of Neurofibromatosis Type 1-Associated Plexiform Neurofibromas. Neuro Oncol. 2022 Jun 03.
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics. Neurology. 2020 06 16; 94(24):e2521-e2531.
Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. Acad Radiol. 2018 02; 25(2):144-152.
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S31-9.
Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014 May; 39(5):e301-7.
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014 Jun; 164A(6):1431-7.
Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem. 2013 May; 46(7-8):698-700.
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711.
Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol. 2009 May 20; 27(15_suppl):2074.
Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar; 250(3):665-73.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.